Loading
Eganelisib is an experimental oral small-molecule kinase inhibitor from Stelexis BioSciences, in phase 2 trials for acute myeloid leukaemia, higher-risk myelodysplastic syndromes and chronic myelomonocytic leukaemia and other cancers.
Eganelisib (IPI-549) is an oral small-molecule kinase inhibitor from Stelexis BioSciences, with Infinity Pharmaceuticals as partner. An oral inhibitor of the enzyme PI3K-gamma, whose catalytic subunit is encoded by PIK3CG. Its furthest stage is phase 2, for acute myeloid leukaemia, higher-risk myelodysplastic syndromes, chronic myelomonocytic leukaemia and urothelial carcinoma (earlier Infinity trials). ClinicalTrials.gov registers it in 4 studies linked below. Highest stage reached is phase 2 under Infinity Pharmaceuticals (e.g. MARIO-275 in urothelial carcinoma, NCT03980041, completed). Under Stelexis: phase 1b in relapsed/refractory AML and higher-risk MDS recruiting (NCT06533761); investigator-sponsored GAVEL phase 1 with azacitidine and venetoclax in AML recruiting (NCT07439211, Stelexis collaborator). Company plans a first-line azacitidine + eganelisib study in PI3K-gamma-high HR-MDS starting 2H26. Whether it works in people has not been established unless a trial below reports it.
An oral inhibitor of the enzyme PI3K-gamma, whose catalytic subunit is encoded by PIK3CG. Connects to PIK3CG.
1.Eganelisib slips into a pocket on PIK3CG.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Eganelisib" OR ABSTRACT:"Eganelisib" OR TITLE:"eganelisib" OR ABSTRACT:"eganelisib" OR TITLE:"IPI-549" OR ABSTRACT:"IPI-549") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Eganelisib, not a curated reading list.
Shares Higher-risk myelodysplastic syndromes, Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Acute myeloid leukaemia and the tag pipeline.
Shares Bladder & urothelial cancer, Head and neck squamous cell carcinoma, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia and the tag pipeline.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/